• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 61Cost-effectiveness of re-treatment using peginterferon alfa-2b and ribavirin combination therapy in previously treated patients – applying early stopping rule for patients not demonstrating an EVR

Re-treatmentCost (£)Outcome (life-years)Outcome (QALYs)ICER (£/QALY gained)
Genotypes 1 + 4
BSC26,22116.7510.74
PEG α-2b29,47617.1211.17
Incremental32560.370.427681
Genotypes 2 + 3
BSC26,22116.7510.74
PEG α-2b23,37118.2112.47
Incremental−28501.471.73PEG α-2b dominates

PEG α, peginterferon alfa.

From: 5, Economic analysis

Cover of Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation
Peginterferon Alfa and Ribavirin for Chronic Hepatitis C in Patients Eligible for Shortened Treatment, Re-Treatment or in HCV/HIV Co-Infection: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.17.
Hartwell D, Jones J, Baxter L, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.